课题基金 / 基金详情

Metabolic signatures of triple negative breast cancer sensitivity and resistance to cyclophosphamide and doxorubicin in patient derived tumor xenografts

Metabolic signatures of triple negative breast cancer sensitivity and resistance to cyclophosphamide and doxorubicin in patient derived tumor xenografts
患者来源的肿瘤异种移植物中三阴性乳腺癌对环磷酰胺和阿霉素的敏感性和耐药性的代谢特征
批准号：
376831
负责人：
Velenosi Thomas J
金额：
$10.93万
依托单位：
National Cancer Institute (Bethesda, Maryland)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-11-01 至 2020-11-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=376831&lang=en
关键词：
Breast Cancer Drug Resistance Metabolomics Pharmacology

项目摘要

项目成果

Velenosi Thomas J的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Breast cancer is the most common type of cancer in women and the second leading cause of cancer related mortality. Approximately 1-in-8 women will be diagnosed with breast cancer in their lifetime. Advances in breast cancer research have identified three
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Characterizing diacetylspermine as a biomarker of drug response and precision treatment in triple-negative breast cancer
  • 批准号：
    494927
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2023
  • 负责人：
    Velenosi Thomas J
  • 依托单位：
    University of British Columbia
Characterizing and validating diacetylspermine as a metabolic biomarker of drug response and precision treatment in triple-negative breast cancer
  • 批准号：
    472346
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2022
  • 负责人：
    Velenosi Thomas J
  • 依托单位：
    University of British Columbia
海外基金